Alnylam
ALNY
Performance
About Alnylam
Alnylam is a biopharmaceutical company focused on discovering and developing RNA interference (RNAi) therapeutics to treat rare and prevalent diseases. The company operates globally, with pipelines and programs across multiple therapeutic areas, including conditions like amyloidosis, primary hyperoxaluria, and acute hepatic porphyria. Alnylam emphasizes science-driven innovation to silence disease-causing genes at the source, aiming to deliver transformative medicines for patients. The organization highlights patient-centric approaches, corporate responsibility, and collaboration with partners to advance RNAi-based therapies.
Recent News
Friday's TechBio News 📰
Alnylam Hops on AI Train with up to $2B Inceptive Partnership
Enhancing Alzheimer Disease Detection Using Neuropsychiatric Symptoms: The Role of Mild Behavioral Impairment in the Revised NIA-AA Research Framework
Indian Researchers Unveil Dual‑siRNA Nanocarrier That Halts Breast Tumor Growth
FDA Clarifies Lumasiran's PH1 Approval, Keeps Givlaari as AHP Treatment
Alnylam and Inceptive Enter ~$2B Collaboration to Accelerate AI-Powered Discovery of RNAi Therapeutics
City Therapeutics Secures $99.5 Million to Advance Next‑Gen RNAi Drugs
STAT+: Alnylam to Partner with Inceptive Nucleics for AI Foundation Models for RNAi Therapeutics
Top 10 Most Innovative Pharma Companies of 2026, Per Fast Company
City Therapeutics Builds RNAi Pipeline with $99.5M Series B